William Blair & Company
TEVA icon

William Blair & Company’s Teva Pharmaceuticals TEVA Stock Holding History

William Blair & Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100
Closed -$3K – 1670
2017
Q1 		$3K Buy
+100
New +$3.41K ﹤0.01% 1446

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

William Blair & Company's TEVA Position: Q2 2026 in Review

William Blair & Company increased its Teva Pharmaceuticals (TEVA) stake by 89% in Q2 2026, buying an estimated $417K and bringing the position to 26,635 shares worth $902K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

William Blair & Company first reported a position in TEVA in Q2 2013 and has held it in 51 quarters since. The position peaked at $344M in Q1 2015. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • William Blair & Company held 26,635 shares of Teva Pharmaceuticals worth $902K as of Q2 2026.
  • William Blair & Company bought 12,531 Teva Pharmaceuticals shares in Q2 2026, an estimated $417K.
  • Teva Pharmaceuticals made up ﹤0.01% of William Blair & Company's portfolio in Q2 2026, its #1015 holding.
  • William Blair & Company first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
  • William Blair & Company's Teva Pharmaceuticals position peaked at $344M in Q1 2015.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on William Blair & Company's 13F filing for Q2 2026, filed 11 Aug 2026.